Roche Pakistan Limited is part of the International F. Hoffmann-La Roche Group that was founded in 1896 in Basel, Switzerland. Roche has grown from a small drug laboratory into one of the world's leading research-based healthcare companies and is known for many innovative contributions to medicine.
Roche products were available in the Indian sub-continent much before Partition. After Pakistan emerged on the world map, imports continued and after a few years some products started to be manufactured in Karachi. In 1984, the foundation of the Roche plant was laid in the Korangi Industrial Area on the outskirts of Karachi. Within a span of three years the plant was constructed and Roche Pakistan started local manufacturing in October 1987.
In recent years, as Roche Pakistan's strategic focus moved towards its biotechnology medicines meant for the treatment of cancer, hematology and rare diseases, most of the traditional Pharmaceutical business along with the factory were divested in 2010.
Today, Roche Pakistan’s business covers both Pharmaceuticals and Diagnostics. In the Pharma market, Roche is ranked among the top companies, while in the Diagnostic sector, Roche is the market leader. The combined strengths of our Diagnostics and Pharmaceutical businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients' needs. Roche's products and services address the entire healthcare spectrum, from screening for genetic risk factors to preventing, diagnosing and treating disease and monitoring the treatment response.
At Roche, we believe there is an urgent need to address the huge inequities in access to healthcare around the world, especially in countries like ours.The burden of expenses, especially for non-communicable diseases like cancer and rare diseases, looms large. We know that countless patients are unable to secure adequate medical treatment due to financial constraints. We also recognise that we have a responsibility to do something about it. Hence in 2017, we launched our Patient Support Program, UNMOL.
UNMOL, an Urdu term meaning 'precious,' is a dynamic Patient Support Program that aims to improve access to healthcare for the underprivileged by offering a sustainable financial solution for those in need of treatment. UNMOL seeks to support patients by contributing to the cost of treatment by providing free of cost medicines through partnerships and public funding programs.
Status of the Company: Public Unlisted Company
Company Registration Number: 0001857
Company NTN Number: 0711885-6
Name of Auditor: KPMG Taseer Hadi & Co.
Name of Legal Advisor: Vellani & Vellani, Fazleghani Associates
Shareholding Pattern: Wholly owned subsidiary of Roche Holding Limited, Switzerland
Board of Directors: Hafsa Shamsie, Farhan Bhatti, Badaruddin F. Vellani
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.